Technical Analysis for PRRUF - Immutep Ltd

Grade Last Price % Change Price Change
F 0.295 0.00% 0.0000
PRRUF closed unchanged on Friday, January 22, 2021, on 7 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A N/A Down
Historical PRRUF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 3.15%
Hot IPO Pullback Bullish Swing Setup 3.15%
Narrow Range Bar Range Contraction 3.15%
Wide Bands Range Expansion 3.15%
Gapped Down Weakness 3.15%
Lower Bollinger Band Touch Weakness 3.15%
20 DMA Resistance Bearish -1.67%
Older End-of-Day Signals for PRRUF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immutep Ltd Description

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), which is in a Phase II and Phase I clinical trials for the treatment of metastatic breast cancer and solid tumors. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP701 for cancer; and IMP731 and IMP761 for autoimmune disease. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.


Keywords: Biotechnology Cancer Clinical Medicine Drugs Treatment Of Cancer Breast Cancer Autoimmune Diseases Solid Tumors Therapeutic Product Autoimmune Disease Cancer Immunotherapy Cancer Treatments Activation Therapeutic Products Alpha T Cell Melanoma L1 Antineoplastic Drugs Biological Products Thk Immunotherapeutic Metastatic Breast Cancer Glaxosmithkline Lymphocyte Metastatic Melanoma Novartis Immunotherapeutic Products Immutep Orphan Drugs Treatment Of Metastatic Breast Cancer

Is PRRUF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.8
52 Week Low 0.135
Average Volume 62,190
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.3075
10-Day Moving Average 0.2996
Average True Range 0.0777
ADX 54.9
+DI 38.5939
-DI 15.7265
Chandelier Exit (Long, 3 ATRs ) 0.1969
Chandelier Exit (Short, 3 ATRs ) 0.4831
Upper Bollinger Band 0.3499
Lower Bollinger Band 0.2651
Percent B (%b) 0.35
BandWidth 27.5772
MACD Line -0.0293
MACD Signal Line -0.0293
MACD Histogram 0.0
Fundamentals Value
Market Cap 892.69 Million
Num Shares 3.03 Billion
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2950
Resistance 3 (R3) 0.2950 0.2950 0.2950
Resistance 2 (R2) 0.2950 0.2950 0.2950 0.2950
Resistance 1 (R1) 0.2950 0.2950 0.2950 0.2950 0.2950
Pivot Point 0.2950 0.2950 0.2950 0.2950 0.2950
Support 1 (S1) 0.2950 0.2950 0.2950 0.2950 0.2950
Support 2 (S2) 0.2950 0.2950 0.2950 0.2950
Support 3 (S3) 0.2950 0.2950 0.2950
Support 4 (S4) 0.2950